Angela Gutierrez-Camino

Angela Gutierrez-Camino

Auto-generated profile, based on publicly available information

Angela Gutierrez-Camino

Paediatric Oncology Group, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2014 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
MHM A H Den Hoed
M A H Den Hoed
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
MWM L Te Winkel
M L Te Winkel
WTW Tissing
W Tissing
JRJ D E de Rooij
J D E de Rooij
MHM M van Den Heuvel-Eibrink
M M van Den Heuvel-Eibrink

16 May 2016 in Pharmacogenomics
Verified
Journal Article
Closed access
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
IAItziar Astigarraga
Itziar Astigarraga
ANAurora Navajas
Aurora Navajas
AEAizpea Echebarria-Barona
Aizpea Echebarria-Barona
AGAfrica Garcia-Orad
Africa Garcia-Orad
Aim: Vincristine is an important component of acute lymphoblastic leukemia (ALL) treatment protocols that can cause neurotoxicity. Patients treated with LAL/SHOP protocols often suffer from vincristine-related neurotoxicity in early phases of treatment. Recently, a genome-wide association study connected a SNP in CEP72, involved in vincristine pharmacodynamics, with neurotoxicity during later phases of therapy, which was not replicated during induction phase. These results, together with previous studies indicating that polymorphisms in pharmacokinetic genes are associated with drug toxicity, suggest that changes in the activity or levels of vincristine transporters or metabolizers could work as predictors of vincristine-related neurotoxicity in early phases of treatment in pediatric ALL. Patients & methods: We analyzed 150 SNPs in eight key genes involved in vincristine pharmacokinetics and in 13 miRNAs that regulate them. We studied their correlation with neurotoxicity during induction phase in 152 ALL ...

1 February 2016 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
AEAizpea Echebarria-Barona
Aizpea Echebarria-Barona
IZIñaki Zabalza
Iñaki Zabalza
AGAfrica Garcia-Orad
Africa Garcia-Orad
Vincristine is a component of acute lymphoblastic leukemia (ALL) treatment with the potential to induce peripheral neuropathy. Recently, the CEP72 rs924607 TT genotype was found to be associated with vincristine-induced toxicity during the continuation phase in pediatric ALL patients treated on the Total XIIIB and COG AALL0433 protocols at St Jude Children's Research Hospital and Children's Oncology Group. This finding could provide a base for safer dosing of vincristine. Nevertheless, there are variations in vincristine regimens among ALL treatment protocols and phases in different populations. Therefore, the aim of this study was to determine whether the CEP72 rs924607 TT genotype is a useful marker of vincristine neuropathy during induction therapy among Spanish children with B-ALL treated on the LAL-SHOP protocols. No association was found between neurotoxicity during the induction phase and the rs924607 TT genotype. This lack of association could be because of population differences and/or differences in neurotoxicity etiology between induction and continuation phases of treatment.

11 March 2014 in Pediatric Research
Verified
Journal Article
Closed access
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
MPMaria A. Piñan
Maria A. Piñan
PGPurificacion Garcia-Miguel
Purificacion Garcia-Miguel
AGAfrica Garcia-Orad
Africa Garcia-Orad

10 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
ÁGÁngela Gutiérrez-Camino
Ángela Gutiérrez-Camino
MPMaria Ángeles Piñán
Maria Ángeles Piñán
JSJosé Sánchez-Toledo
José Sánchez-Toledo
JUJose Javier Uriz
Jose Javier Uriz
ÁGÁfrica García-Orad
África García-Orad
Despite the clinical success of acute lymphoblastic leukemia (ALL) therapy, toxicity is frequent. Therefore, it would be useful to identify predictors of adverse effects. In the last years, several studies have investigated the relationship between genetic variation and treatment-related toxicity. However, most of these studies are focused in coding regions. Nowadays, it is known that regions that do not codify proteins, such as microRNAs (miRNAs), may have an important regulatory function. MiRNAs can regulate the expression of genes affecting drug response. In fact, the expression of some of those miRNAs has been associated with drug response. Genetic variations affecting miRNAs can modify their function, which may lead to drug sensitivity. The aim of this study was to detect new toxicity markers in pediatric B-ALL, studying miRNA-related polymorphisms, which can affect miRNA levels and function. We analyzed 118 SNPs in pre-miRNAs and miRNA processing genes in association with toxicity in 152 pediatric B-ALL patients all treated with the same protocol (LAL/SHOP). Among the results found, we detected for the first time an association between rs639174 in DROSHA and vomits that remained statistically significant after FDR correction. DROSHA had been associated with alterations in miRNAs expression, which could affect genes involved in drug transport. This suggests that miRNA-related SNPs could be a useful tool for toxicity prediction in pediatric B-ALL.

1 July 2014 in Pharmacogenomics
Verified
Journal Article
Closed access
ELElixabet Lopez-Lopez
Elixabet Lopez-Lopez
AGAngela Gutierrez-Camino
Angela Gutierrez-Camino
NBNerea Bilbao-Aldaiturriaga
Nerea Bilbao-Aldaiturriaga
MPMaria Pombar-Gomez
Maria Pombar-Gomez
IMIdoia Martín-Guerrero
Idoia Martín-Guerrero
AGAfrica Garcia-Orad
Africa Garcia-Orad
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients for which therapy fails while some patients experience severe toxicity. In the last few years, several pharmacogenetic studies have been performed to search for markers of outcome and toxicity in pediatric ALL. However, to date, TPMT is the only pharmacogenetic marker in ALL with clinical guidelines for drug dosing. In this article, we will provide an overview of the most important findings carried out in pharmacogenetics for pediatric ALL, such as the interest drawn by methotrexate transporters in the context of methotrexate treatment. Even if most of the studies are centered on coding genes, we will also point to new approaches focusing on noncoding regions and epigenetic variation that could be interesting for consideration in the near future.